» Articles » PMID: 9357554

Elevated Levels of the Kearns-Sayre Syndrome Mitochondrial DNA Deletion in Temporal Cortex of Alzheimer's Patients

Overview
Journal Mutat Res
Publisher Elsevier
Specialty Genetics
Date 1997 Nov 14
PMID 9357554
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

A mitochondrial hypothesis of Alzheimer's disease (AD) has been proposed based on a number of studies which establish altered oxidative phosphorylation (OXPHOS) and ATP synthesis in AD tissue. Four out of five complexes in the OXPHOS pathway are partly encoded by mitochondrial DNA (mtDNA); thus, this may be a crucial site of lesions that alter brain activity. We examined temporal cortex autopsy tissue for deleted mtDNA by PCR-based methods and Southern analysis. AD tissue was obtained from autopsy-confirmed cases that had a postmortem delay ranging from 5 to 27 h. Using a rat brain model system to examine postmortem effects by Southern analysis, no evidence of mtDNA degradation after 30 h of postmortem delay at room temperature was found. Nine tissue samples taken from AD autopsy brain (average age 68 years) and nine age-matched controls (average age 66 years) were assessed by serial dilution PCR for the 5 kb deletion (mtDNA delta 4977) previously associated with Kearns-Sayre syndrome. Using this method we determined that AD temporal cortex had a 6.5-fold greater frequency of mtDNA delta 4977 than controls (0.0593% vs. 0.0092%, p = 0.0269, one-tailed; p = 0.0530, two-tailed), indicating that damaged mtDNA preferentially accumulates in AD compared to aged brain.

Citing Articles

The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer's disease.

Quan S, Fu X, Cai H, Ren Z, Xu Y, Jia L Mol Neurodegener. 2025; 20(1):25.

PMID: 40038765 PMC: 11877805. DOI: 10.1186/s13024-025-00815-2.


Exosome-associated mitochondrial DNA in late-life depression: Implications for cognitive decline in older adults.

Mendes-Silva A, Nikolova Y, Rajji T, Kennedy J, Diniz B, Goncalves V J Affect Disord. 2024; 362:217-224.

PMID: 38945405 PMC: 11316645. DOI: 10.1016/j.jad.2024.06.092.


Mitochondria and Brain Disease: A Comprehensive Review of Pathological Mechanisms and Therapeutic Opportunities.

Clemente-Suarez V, Redondo-Florez L, Beltran-Velasco A, Ramos-Campo D, Belinchon-deMiguel P, Martinez-Guardado I Biomedicines. 2023; 11(9).

PMID: 37760929 PMC: 10526226. DOI: 10.3390/biomedicines11092488.


Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.

Austad S, Ballinger S, Buford T, Carter C, Smith Jr D, Darley-Usmar V Acta Pharm Sin B. 2022; 12(2):511-531.

PMID: 35256932 PMC: 8897048. DOI: 10.1016/j.apsb.2021.06.014.


Comprehensive summary of mitochondrial DNA alterations in the postmortem human brain: A systematic review.

Valiente-Palleja A, Tortajada J, Bulduk B, Vilella E, Garrabou G, Muntane G EBioMedicine. 2022; 76:103815.

PMID: 35085849 PMC: 8790490. DOI: 10.1016/j.ebiom.2022.103815.